AU7211591A - Immunologically active peptides or polypeptides from the parvovirus b19 - Google Patents

Immunologically active peptides or polypeptides from the parvovirus b19

Info

Publication number
AU7211591A
AU7211591A AU72115/91A AU7211591A AU7211591A AU 7211591 A AU7211591 A AU 7211591A AU 72115/91 A AU72115/91 A AU 72115/91A AU 7211591 A AU7211591 A AU 7211591A AU 7211591 A AU7211591 A AU 7211591A
Authority
AU
Australia
Prior art keywords
gene
parvovirus
antigens
polypeptides
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU72115/91A
Other versions
AU650864B2 (en
Inventor
Manfred Motz
Erwin Soutschek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIKROGEN MOLEKULARBIOLOGISCHE ENTWICKLUNGS-GMBH
Original Assignee
Mikrogen Molekularbiologische Entw GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikrogen Molekularbiologische Entw GmbH filed Critical Mikrogen Molekularbiologische Entw GmbH
Publication of AU7211591A publication Critical patent/AU7211591A/en
Application granted granted Critical
Publication of AU650864B2 publication Critical patent/AU650864B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Immunologically active peptides or polypeptides with a partial amino acid sequence of the capside protein VP1 and VP2 of parvovirus B19 are obtained which provide an economical, sensitive and specific test to detect antibodies against the human parvovirus B19. Short peptide sequences are identified which when used as an antigen serve to identify anti-B19 IgG-positive sera. The production of these peptides by gene-technological means is revealed. Other gene-technologically produced antigens which form stably in large quantities in E. Coli and can subsequently be separated from them act as additional antigens for IgG confirmation. Finally a set of antigens facilitates testing for the detection of IgM antibodies against the virus. In addition, the gene-technologically produced components of the surface proteins are substances which may be used for prophylactic immunisation.
AU72115/91A 1990-02-08 1991-02-08 Immunologically active peptides or polypeptides from the parvovirus B19 Expired AU650864B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4003826 1990-02-08
DE4003826A DE4003826C2 (en) 1990-02-08 1990-02-08 Peptides of the capsid proteins VP1 or VP2 of the parvovirus B19
PCT/DE1991/000106 WO1991012269A1 (en) 1990-02-08 1991-02-08 Immunologically active peptides or polypeptides from the parvovirus b19

Publications (2)

Publication Number Publication Date
AU7211591A true AU7211591A (en) 1991-09-03
AU650864B2 AU650864B2 (en) 1994-07-07

Family

ID=6399718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72115/91A Expired AU650864B2 (en) 1990-02-08 1991-02-08 Immunologically active peptides or polypeptides from the parvovirus B19

Country Status (9)

Country Link
EP (1) EP0514413B1 (en)
JP (2) JP3061196B2 (en)
AT (1) ATE105303T1 (en)
AU (1) AU650864B2 (en)
CA (1) CA2075366C (en)
DE (2) DE4003826C2 (en)
DK (1) DK0514413T3 (en)
ES (1) ES2052370T3 (en)
WO (1) WO1991012269A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680264B2 (en) * 1993-01-23 1997-07-24 Inmunologia Y Genetica Aplicada, S.A. Synthetic peptides and vaccines against parvovirus

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149116B2 (en) * 1992-10-28 2001-03-26 信越化学工業株式会社 Epitope-related peptide of human parvovirus
EP0725837B1 (en) * 1993-10-28 2000-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Adeno-associated virus - its diagnostic use with early abortion
AU5103396A (en) * 1995-03-08 1996-09-23 Klaus Hedman Method for the diagnosis of injections
JPH0910000A (en) 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya Detection of human parvovirus and reagent therefor
FR2771751B1 (en) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris ERYTHROVIRUS AND ITS APPLICATIONS
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6743772B1 (en) 1998-11-24 2004-06-01 Kristina Broliden Use of parovirus capsid particles in the inhibition of cell proliferation and migration
US6818612B2 (en) 1998-11-24 2004-11-16 Kristina Broliden Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
KR100888377B1 (en) 2001-06-28 2009-03-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Diagnostic assays for parvovirus b19
CA2456715A1 (en) 2001-08-31 2003-03-13 Gen-Probe Incorporated Assay for detection of human parvovirus b19 nucleic acid
WO2007096199A2 (en) * 2006-02-22 2007-08-30 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Differential diagnostics and therapy of virally induced heart muscle disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002026A1 (en) * 1986-09-08 1988-03-24 Applied Biotechnology, Inc. Empty viral capsid vaccines
DE3939470A1 (en) * 1989-11-29 1991-06-06 Biochrom Beteiligungs Gmbh & C Diagnosis and prevention of human parvovirus B19 infection - using synthetic penta- and higher peptide(s) and antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680264B2 (en) * 1993-01-23 1997-07-24 Inmunologia Y Genetica Aplicada, S.A. Synthetic peptides and vaccines against parvovirus

Also Published As

Publication number Publication date
JPH05504143A (en) 1993-07-01
WO1991012269A1 (en) 1991-08-22
EP0514413A1 (en) 1992-11-25
ATE105303T1 (en) 1994-05-15
AU650864B2 (en) 1994-07-07
DE59101577D1 (en) 1994-06-09
JP2000184889A (en) 2000-07-04
CA2075366C (en) 2003-02-18
DE4003826C2 (en) 1995-11-23
ES2052370T3 (en) 1994-07-01
JP3130024B2 (en) 2001-01-31
CA2075366A1 (en) 1991-08-09
JP3061196B2 (en) 2000-07-10
DK0514413T3 (en) 1994-06-06
DE4003826A1 (en) 1991-08-14
EP0514413B1 (en) 1994-05-04

Similar Documents

Publication Publication Date Title
Hampar et al. Heterogeneity in the properties of 7 S and 19 S rabbit-neutralizing antibodies to herpes simplex virus
Dietzschold et al. Chemical and immunological analysis of the rabies soluble glycoprotein
GR940300008T1 (en)
EP0442394A3 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
DK0522030T3 (en) Hepatitis B vaccine
DE69327587D1 (en) Conjugates of weakly immunogenic antigenic and synthetic peptide carriers and vaccines containing them
AU7211591A (en) Immunologically active peptides or polypeptides from the parvovirus b19
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
DK0469045T3 (en) Synthetic Pseudomonas aeruginosa pilin peptides and related vaccines diagnostics
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP0582243A3 (en) HCV peptide antigens and a method of testing for the hepatitis C virus (HCV).
FI854839A (en) VACCIN ELLER DIAGNOSTIC PRODUCT ERHAOLLEN FRAON PEPTID, SAMT DAERI ANVAENDBAR POLYPEPTID.
DE69017352D1 (en) Peptides related to HIV.
JPH03503416A (en) peptide
ATE134648T1 (en) ARTIFICIAL POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN
IT1250366B (en) Recombinant protein material binding antibodies against human cytomegalovirus, diagnostic reagents derived from that protein material and recombinant plasmids expressing the same
IT1250367B (en) Antibody binding protein material against human cytomegalovirus and diagnostic reagents derived from that protein material